Policy

Thanks to significant recent progress in HIV vaccine research and development, scientists are increasingly confident that HIV vaccines will someday become available for general use. The only question is when that will happen. Getting there will require both sustained support for global HIV vaccine R&D and a policy environment that continues to encourage and enable such efforts. Cognizent of those needs, IAVI and its partners strive to:

To achieve these goals, IAVI works in concert with its advocacy and technical partners, including AVAC: Global Advocacy for HIV Prevention, the Futures Institute, the Global Health Technologies Coalition, the International Partnership for Microbicides and the Joint United Nations Programme on HIV/AIDS (UNAIDS).

Resource Tracking

The HIV Vaccines and Microbicides Resource Tracking Working Group was founded in 2004 to track global resources dedicated to the research and development of new biomedical tools for HIV prevention. The Working Group is a collaboration between AVAC: Global Advocacy for HIV Prevention, IAVI, and the Joint United Nations Programme on HIV/AIDS (UNAIDS). Funding data assembled by the Working Group date back to 2000 and have enabled the systematic tracking of investments and trends in the advancement of new tools and strategies to prevent HIV.

The most recent report, HIV Prevention Research & Development Investment in 2013: In a changing global development, economic, and human rights landscape, was issued in July 2014. It covers investments through 2013 on preventive and therapeutic vaccines against HIV, microbicides, adult male circumcision, female condoms, pre-exposure prophylaxis (PrEP), and HSV-2 prevention, as well as developing and improving strategies for prevention of mother-to-child vertical HIV transmission at birth and during breastfeeding.

Global preventive AIDS vaccine R&D investment totaled US$818 million in 2013, with the public sector providing US$666 million (81%), the philanthropic sector providing US$121 million (15%), and the commercial sector contributing US$31 million (4%). The 2013 total investment represents a decrease of US$29 million (4%) below global preventive AIDS vaccine R&D investment in 2012.

The United States government remained by far the largest investor in AIDS vaccines, providing US$585 million in 2013, even though total U.S. government funding decreased by US$38 million from 2012, driven by mandated across-the-board federal budget cuts. Funding from European public sector agencies totaled US$44 million, after reductions of almost US$8 million (15%) from 2012.

Funding from philanthropic supporters for AIDS vaccines grew by around US$10 million dollars (approximately 10%) from 2012 to 2013. Meanwhile, estimated commercial funding in 2012 remained relatively flat at US$31 million. The AIDS vaccine field has produced an abundance of promising data in recent years. However, given the long-term nature of AIDS vaccine development, its continued progress will require flexible and sustained investments in research and development.

AIDS Vaccine Funding, 2000-2013

AIDS Vaccine Funding, 2000-2013

For more information on the Working Group, archived reports and materials, and information on its members, please visit http://www.hivresourcetracking.org.

Impact Modeling

IAVI and the Futures Institute, with support from the U.S. Agency for International Development (USAID), have developed a model that predicts the impact that preventive AIDS vaccines could have on HIV epidemics at both national and global levels. Such projections can assist policymakers, vaccine developers, advocates and funders make informed decisions and effective resource allocations. 

The model shows that a vaccine could avert millions of new HIV infections and play a crucial role in ending the AIDS pandemic, even if current targets for access to HIV prevention, treatment and care are reached before a vaccine is introduced.

IAVI’s new suite of modeling publications explores an AIDS vaccine’s potential impact in low- and middle-income countries in terms of infections averted, the specific impact on women and girls, and the potential cost-savings a vaccine could provide by reducing the number of people in need of life-saving antiretroviral treatment. IAVI and the Futures Institute also have collaborated with researchers and policymakers on country-level in Kenya, Uganda, Brazil and China.

To learn more about IAVI and the Futures Institute’s impact modeling work, visit IAVI’s policy studies database

Interactive Impact Modeling Tool
Explore the interaction of future potential preventive AIDS vaccines with existing HIV-prevention tools within an HIV epidemic representative of one of five regions.